RUSAL (00486) reported an annual adjusted net loss of 787 million US dollars, a turnaround from profit to loss year-on-year.
Rusal (00486) released its annual performance up to December 31, 2025. The group achieved a revenue of $14.812 billion in the period, a year-on-year increase of 22.6%. The adjusted net loss was $787 million, a year-on-year conversion from profit to loss, with a basic loss per share of $0.03.
RUSAL (00486) announced its annual performance for the year ended December 31, 2025, with revenue of $14.812 billion, an increase of 22.6% year-on-year; adjusted net loss of $787 million, a turnaround from profit to loss year-on-year; basic loss per share of $0.03.
For the year ended December 31, 2025, the group's primary aluminum production was 3,918 thousand tons, a decrease of approximately 1.9% compared to 3,992 thousand tons in the same period in 2024.
In 2025, aluminum sales increased by 16.4% to 4,490 thousand tons, compared to 3,859 thousand tons in 2024. During the period, sales of Value-Added Products (VAP) increased by 6.0% to 1,507 thousand tons (compared to 1,422 thousand tons in 2024). VAP sales accounted for 34% of total sales (compared to 37% in 2024).
In 2025, RUSAL's total alumina production reached 6,858 thousand tons, compared to 6,430 thousand tons in 2024, an increase of 6.7% due to the acquisition of a 30% stake in China's Hebei Wenfeng New Materials Co., Ltd. (accounted for from April 2024) and a 26% stake in India's Pioneer Aluminium Industries Limited (accounted for from July 2025).
In 2025, RUSAL's total bauxite production reached 18,453 thousand tons, compared to 15,885 thousand tons in 2024, an increase of 16.2% primarily due to the expansion of production capacity at the CBK and Dian-Dian facilities.
Related Articles

HK Stock Market Move | RemeGen (09995) rose nearly 8% again, and multiple original research results on vedolizumab were released at the 2026 EAU conference.

HK Stock Market Move | CF PHARMTECH (02652) rose more than 21% in midday trading, with the innovative research and development pipeline for high-end respiratory system formulations entering a period of accelerated harvest.

CICC: Maintains Outperform rating on GENSCRIPT BIO (01548), lowers target price to HK$17.90.
HK Stock Market Move | RemeGen (09995) rose nearly 8% again, and multiple original research results on vedolizumab were released at the 2026 EAU conference.

HK Stock Market Move | CF PHARMTECH (02652) rose more than 21% in midday trading, with the innovative research and development pipeline for high-end respiratory system formulations entering a period of accelerated harvest.

CICC: Maintains Outperform rating on GENSCRIPT BIO (01548), lowers target price to HK$17.90.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


